- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07585955
Family Connections Transdiagnostic for Relatives of People With Emotional Dysregulation (FC-T)
Family Connections Transdiagnostic: Study Protocol for a Randomized Controlled Trial Evaluating Efficacy in Relatives of People With Emotional Dysregulation
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Emotional dysregulation (ED) is a core transdiagnostic process characterized by heightened emotional sensitivity, intense emotional responses, and difficulties returning to baseline emotional states. It is present across a wide range of psychological disorders, including eating disorders (EDs), Cluster B personality disorders (PD), and disruptive, impulse-control, and conduct disorders. These conditions are associated with significant impairments in social functioning and are often accompanied by psychological symptoms such as depression, anxiety, interpersonal difficulties, and reduced quality of life. In addition, maladaptive strategies to cope with emotional distress (e.g., self-harm, impulsivity, aggression, binge eating) contribute to the maintenance and severity of these disorders.
Families of individuals with psychological disorders characterized by ED experience a high burden of illness and frequently report elevated levels of psychological distress, including anxiety and depression, as well as impairments in their own quality of life. Despite their key role as primary caregivers, family members often lack the necessary skills to effectively manage emotional crises and daily challenges, which may contribute to dysfunctional family dynamics and increased conflict. Although some intervention programs have been developed for caregivers of specific disorders, there is currently a lack of transdiagnostic treatments specifically designed for relatives of individuals with ED.
A skills training program called "Family Connections" (FC) was developed by Hoffman and Fruzzetti's group for relatives of individuals with borderline personality disorder (BPD). It is a program consisting of 12 weekly two-hour sessions delivered in a group format. It is divided into six modules that include psychoeducation about the disorder and its impact on family functioning, as well as skills adapted from Dialectical Behavior Therapy, such as mindfulness, emotion regulation, validation, radical acceptance, and problem management, among others. In addition, all modules include practical exercises, video examples, and homework assignments. Previous studies have shown that this program leads to significant reductions in caregiver burden, perceived distress, depression, and anxiety, as well as improvements in coping strategies and family functioning.
The present study aims to develop and evaluate a transdiagnostic adaptation of the program (Family Connections Transdiagnostic; FC-T), designed to be applied to relatives of individuals with psychological disorders characterized by emotional dysregulation, regardless of specific diagnosis. The psychoeducational modules will be adapted to address ED as a common underlying mechanism, while maintaining the core skills training components of the original program.
The aims of this study are the following: (a) to adapt and test, in the Spanish population, the modules of the FC-T intervention protocol for relatives of patients with psychological disorders characterized by ED; (b) to test the efficacy of FC-T in reducing caregiver burden and clinical symptomatology and improving family relationships and quality of life; (c) to test its efficiency, understood as the acceptance of the intervention program by participants and clinicians, and to demonstrate its feasibility; and (d) to carry out an effective dissemination of this protocol.
This paper presents the study protocol. The study design consists of a two-arm randomized controlled trial with two conditions: Family Connections Transdiagnostic (FC-T) or Treatment as usual optimized (TAU-O). Participants will be family members of patients diagnosed, according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), with eating disorders, Cluster B personality disorders, or disruptive, impulse-control, and conduct disorders. The caregivers' primary outcome measures will be the Burden Assessment Scale (BAS) and a Family-Patient Critical Incident Record. Secondary outcomes will include measures of family functioning, clinical symptomatology, coping strategies, and quality of life. Patient-related outcomes will include measures of emotional dysregulation and impulsivity. Participants will be assessed at pre-treatment, post-treatment, and twelve-month follow-up. The intention-to-treat principle will be used when analyzing data, using mixed-effects models with full information and maximum likelihood estimation.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Valencia
-
Valencia, Valencia, Espagne, 46010
- University of Valencia
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
• Being 18 years of age or older.
- Being a family member (e.g., parent, partner, sibling, or other close relative) of a patient diagnosed, according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), with a psychological disorder characterized by emotional dysregulation (e.g., eating disorders, Cluster B personality disorders, or disruptive, impulse-control, and conduct disorders).
- The patient must currently be receiving treatment in a participating clinical center.
- Having sufficient knowledge and understanding of the Spanish language to complete the assessments and participate in the intervention.
- Providing written informed consent to participate in the study.
Exclusion Criteria:
• Presence of any severe mental disorder or condition in the family member that may interfere with participation in the intervention (e.g., psychotic disorders, schizophrenia, severe cognitive impairment, or intellectual disability).
- Current substance dependence that may hinder participation in the study.
- Severe clinical instability in the patient that prevents the family member from participating in the intervention (as judged by clinicians).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Family Connections Transdiagnostic for relatives of people with emotional dysregulation
- 12 weekly group sessions (2 hours each) Modules:
|
The intervention lasts 3 months and includes 12 two-hour sessions in a group format on a weekly basis.
The FC-T program is divided into 6 modules: 2 modules of psychoeducation on emotional dysregulation (ED) and 4 modules of Dialectical Behavior Therapy (DBT)-based skills training (relationship mindfulness, emotional regulation, acceptance, validation, and problem management).
|
|
Comparateur actif: Optimized Treatment as Usual (TAU-O)
Usual care + psychoeducational session on ED
|
Family members will receive the usual care available in their clinical setting.
In addition, they will participate in a single 3-hour group psychoeducation session including the following components: (1) up-to-date information and research on emotional dysregulation (epidemiology, frequency, comorbidity, risk and protective factors); and (2) psychoeducation on the development of emotional dysregulation, explanatory models, and available treatments.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Record of critical family-patient incidents
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
Frequency of problem behaviors in the past 3 months, including suicide attempts, self-harm episodes, visits to psychiatric emergency services, episodes of binge eating, substance use (alcohol or drugs), stealing, fire-setting, verbal aggression, and physical aggression.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Burden Assessment Scale (BAS)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a 19-item scale that assesses the caregiver's objective and subjective burden due to the illness of their relative within the past six months using a 4-point Likert scale ranging from 1 (not at all) to 4 (a lot).
Higher scores indicate greater caregiver burden.
The scale shows adequate validity and reliability, with Cronbach's alpha coefficients ranging from .89 to .91.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Family Assessment Device - Global Functioning Scale (FAD-GF)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a 60-item self-report measure of family functioning assessing domains such as communication, roles, affective involvement, and general functioning.
Items are rated on a 4-point Likert scale.
The instrument shows good internal consistency, with Cronbach's alpha coefficients ranging between .72 and .83
for subscales and around .92 for general functioning.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Depression, Anxiety and Stress Scale (DASS-21)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a 21-item scale that measures clinical symptoms such as depression, anxiety, and stress.
Items are rated on a 4-point Likert scale ranging from 0 (did not apply to me) to 3 (applied to me most of the time).
It shows excellent internal consistency, with Cronbach's alpha coefficients of approximately .94 for depression, .87 for anxiety, and .91 for stress.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Quality of Life Index (QLI)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
This instrument assesses perceived quality of life across several domains, including health, psychological well-being, and social relationships.
Higher scores indicate better quality of life.
The Spanish version has demonstrated adequate reliability and validity, with good internal consistency indices.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Mastery and Empowerment Scale (MES)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a 34-item scale that evaluates coping strategies, perceived control, and empowerment across family, service system, and community domains.
Items are rated on a 5-point Likert scale.
Previous studies have demonstrated robust psychometric properties, including good internal consistency and construct validity across different samples.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Opinion of Treatment Scale
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
This scale assesses participants' satisfaction, acceptance, and perceived usefulness of the intervention program.
It evaluates aspects such as satisfaction, perceived effectiveness, and willingness to recommend the program.
Items are rated on a Likert-type scale ranging from 0 to 10.
This measure has been adapted from previous treatment opinion scales and shows adequate face validity for assessing treatment acceptability.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Difficulties in Emotion Regulation Scale (DERS) (for Patients)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a self-report measure assessing difficulties in emotion regulation.
The Spanish adaptation includes 28 items across five dimensions (lack of emotional control, interference in goal-directed behavior, lack of emotional awareness, emotional confusion, and emotional rejection).
Items are rated on a Likert scale from 1 to 5. The scale shows very good internal consistency (Cronbach's alpha ≈ .93)
and good test-retest reliability (r ≈ .74).
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Barratt Impulsiveness Scale (BIS) (for Patients)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
This instrument assesses impulsivity as a multidimensional construct, including attentional, motor, and non-planning impulsivity.
Items are rated on a Likert-type scale.
The Spanish adaptation has demonstrated adequate psychometric properties, including good internal consistency and construct validity.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Family Assessment Device - Global Functioning Scale (FAD-GF) (for Patients)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a self-report measure of family functioning assessing domains such as communication, roles, affective involvement, and general functioning.
It shows good internal consistency, with Cronbach's alpha coefficients ranging from .72 to .83 and up to .92 for general functioning.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Validating and Invalidating Responses Scale (VIRS) (for Patients)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a 16-item scale that assesses perceived validation and invalidation in caregiver responses.
Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (almost always).
The scale has shown adequate internal consistency and construct validity in previous studies.
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
|
Lum Emotional Availability of Parents (LEAP) (for Patients)
Délai: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
It is a 15-item questionnaire that assesses perceived emotional availability of caregivers.
Items are rated on a 6-point Likert scale.
The instrument shows excellent internal consistency (Cronbach's alpha ≈ .92
for mothers and .93 for fathers) and good test-retest reliability (r ≈ .92 and r ≈ .85,
respectively).
|
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Laura Díaz-Sanahuja, Dr. Professor, University of Valencia
- Chaise d'étude: Cayetana Garoz, PhD, University of Castellón
- Chaise d'étude: Álvaro Cadiñanos, PhD, University of Valencia
- Chaise d'étude: Elena González-Perpiñá, PhD, University of Valencia
- Chaise d'étude: Antonio Arnal, PhD, University of Valencia
- Chaise d'étude: Ginnette Muñoz, PhD, University of Valencia
Publications et liens utiles
Publications générales
- Hoffman PD, Fruzzetti AE, Buteau E, Neiditch ER, Penney D, Bruce ML, Hellman F, Struening E. Family connections: a program for relatives of persons with borderline personality disorder. Fam Process. 2005 Jun;44(2):217-25. doi: 10.1111/j.1545-5300.2005.00055.x.
- Hoffman PD, Fruzzetti AE. Advances in interventions for families with a relative with a personality disorder diagnosis. Curr Psychiatry Rep. 2007 Feb;9(1):68-73. doi: 10.1007/s11920-007-0012-z.
- Flynn D, Kells M, Joyce M, Corcoran P, Herley S, Suarez C, Cotter P, Hurley J, Weihrauch M, Groeger J. Family Connections versus optimised treatment-as-usual for family members of individuals with borderline personality disorder: non-randomised controlled study. Borderline Personal Disord Emot Dysregul. 2017 Aug 30;4:18. doi: 10.1186/s40479-017-0069-1. eCollection 2017.
- Guillen V. Psychological interventions for family members of people with psychological disorders with emotional dysregulation: Introduction to special section. Fam Process. 2024 Dec;63(4):2087-2098. doi: 10.1111/famp.13090. Epub 2024 Nov 30.
- Guillen V, Fernandez-Felipe I, Marco JH, Grau A, Botella C, Garcia-Palacios A. "Family Connections", a program for relatives of people with borderline personality disorder: A randomized controlled trial. Fam Process. 2024 Dec;63(4):2195-2214. doi: 10.1111/famp.13089. Epub 2024 Dec 3.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Les troubles mentaux
- Signes et symptômes digestifs
- Troubles neurodéveloppementaux
- Déficit de l'attention et troubles du comportement perturbateur
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Trouble des conduites
- Troubles de la personnalité
- Troubles de l'alimentation et de l'alimentation
Autres numéros d'identification d'étude
- 2025-PSILOG-3866898
- Research proyect (Autre subvention/numéro de financement: Generalitat Valenciana)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .